After the Supreme Court invited the Solicitor General to file a brief expressing the views of the United States regarding Teva Pharms USA, Inc. v. GlaxoSmithKline LLC, et al., the Solicitor General filed its brief amicus curiae on March 29, 2023. The Solicitor General urged the Supreme Court to grant Teva’s petition for a writ
Latest Post
More Posts
Foodtech Patents: Who’s on the Board and What Moves are they Making?
Amgen v. Sanofi Case on Enablement of Antibody Genus Claims Will be Heard at the Supreme Court; Cert Denied in Juno v. Kite
Tysabri® (natalizumab) Litigation Begins
Purple Book Update – Regeneron’s EYLEA (aflibercept)
Will the Supreme Court Take the Bait? CVSG Issued and Other Updates in the Amgen v. Sanofi Case
Not Backing Down Now – Multiple Amicus Curiae Briefs Filed for Amgen v. Sanofi
Laying Down the [Trademark] Law – The USPTO Signals Stricter Enforcement to Come
A Potential Pivot in Patent Procedure – Will the Supreme Court Hear Amgen’s Challenge to the Standard of Review for Enablement?
Subscribe: Subscribe via RSS
Firm/Org